<DOC>
	<DOCNO>NCT01381107</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , parallel , multiple dose study design evaluate safety tolerability co-formulation ALKS 33 buprenorphine ( ALKS 5461 ) subject Major Depressive Disorder ( MDD ) inadequately/partially respond current treatment stable dose serotonin-selective reuptake inhibitor ( SSRI ) serotonin-norepinephrine reuptake inhibitor ( SNRI ) .</brief_summary>
	<brief_title>ALK33BUP-201 : Safety Tolerability Study ALKS 33-BUP ( ALKS 5461 ) Administration Subjects With MDD</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<criteria>Male female subject 18 65 year age , inclusive . Meet Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) criterion MDD . Current episode last ≥8 week prior screen inadequate/partial response adequate trial ( define least 8 week ) stable dose SSRI SNRI . Inadequate/partial response define : 1 . A Hamilton Depression Rating Scale total score ( HAMD17 ) ≥14 , 2 . Less 50 % reduction depressive symptom severity Massachusetts General Hospital Antidepressant Treatment Response Questionnaire ( ATRQ ) , 3 . Clinical Global Impression Severity ( CGIS ) score ≥3 . Axis I diagnosis delirium , dementia , amnestic cognitive disorder , schizophrenia psychotic disorder , bipolar I II disorder , eat disorder , obsessivecompulsive disorder , panic disorder , posttraumatic stress disorder . A clinically significant current Axis II diagnosis borderline , antisocial , paranoid , schizoid , schizotypal , histrionic personality disorder . Experiencing hallucination , delusion , psychotic symptomatology current episode . The use inducer inhibitor cytochrome P450 ( CYP ) 3A4 ( prescription medication , overthecounter [ OTC ] medication , dietary supplement ) within 30 day dose . Have receive electroconvulsive therapy current MDD episode . Pose current suicide risk confirm Columbia Suicide Severity Rating Scale ( C SSRS ) . History intolerance hypersensitivity buprenorphine . History allergy hypersensitivity opioid antagonist ( eg , naltrexone , naloxone ) quinine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>